Roche Strengthens Clinical Research Leadership in Spain with €57M Investment

In 2025, Roche Pharma invested €57 million to boost research. Throughout the past year, the company conducted a total of 283 clinical trials on 76 new molecules, involving 8,584 patients and 950 researchers from 178 healthcare centers across Spain.

According to Mariluz Amador, Medical Director of Roche Pharma Spain, “clinical research is a key activity for generating new solutions to patients’ health problems, but it also offers numerous benefits for the healthcare system and society as a whole.

To mark International Clinical Trials Day, these figures reflect the company’s strong commitment to clinical investment in Spain. “Clinical trials not only allow for the research and development of innovative medicines; they also facilitate, in certain cases, early access to innovation for patients without therapeutic alternatives; they attract significant R&D investment; they foster the creation of new scientific knowledge within the National Health System; they place Spanish healthcare professionals at the forefront of research; and they even generate savings and efficiency improvements in healthcare centers,” Amador explains.

“Clinical research is a key activity for generating new solutions to patients’ health problems,” according to Mariluz Amador of Roche Pharma Spain

In this respect, Spain has the right conditions for conducting these studies due, among other factors, to the high level of training of its healthcare professionals, the quality of its healthcare system, the commitment of the various administrations and health authorities to clinical research, and patient participation. All of this allows Spain to remain the third country in the world in terms of the number of studies and patients recruited within the Roche group, behind only the United States and China.

Both patients and healthcare professionals have the opportunity to consult all of Roche’s ongoing clinical trials in Spain (defining them, their phases, and how patient participation is structured) through a dedicated web platform, as well as information on the clinical research process for various diseases. This tool also provides information on specific clinical trials, including their location, patient recruitment status, exclusion criteria, details about the investigational drug, and a summary of the results in accessible language.

On the other hand, this year Roche Farma has decided to join, along with some twenty innovative companies, the +Trials campaign , promoted by the National Business Association of the Pharmaceutical Industry ( Farmaindustria ) in order to raise awareness in society about the importance of Spain continuing to be a leading country in clinical research in the international context.

__

(Featured image by clickphoto via Pixbay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.